{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:19:18Z","timestamp":1777879158160,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["112-IF000 4"],"award-info":[{"award-number":["112-IF000 4"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jfma.2025.01.012","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T08:10:27Z","timestamp":1737533427000},"page":"283-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term serum ferritin dynamics in patients receiving antiviral treatment for hepatitis C virus infection"],"prefix":"10.1016","volume":"125","author":[{"given":"Yu-Ping","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiuan-Bo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2507-9627","authenticated-orcid":false,"given":"Shang-Chin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Chung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-9707","authenticated-orcid":false,"given":"Chen-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2025.01.012_bib1","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","article-title":"Hepatitis C","volume":"402","author":"Martinello","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2025.01.012_bib2","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.01.012_bib3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.01.012_bib4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s12072-021-10158-x","article-title":"Sofosbuvir\/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan","volume":"15","author":"Liu","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2025.01.012_bib5","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/liv.14295","article-title":"Glecaprevir\/pibrentasvir for patients with chronic hepatitis C virus infection: real-world effectiveness and safety in Taiwan","volume":"40","author":"Liu","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2025.01.012_bib6","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2025.01.012_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10092008","article-title":"Hyperferritinemia-A clinical overview","volume":"10","author":"Sandnes","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jfma.2025.01.012_bib8","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/0016-5085(92)90339-Z","article-title":"Measurements of iron status in patients with chronic hepatitis","volume":"102","author":"Di Bisceglie","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2025.01.012_bib9","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/hep.24787","article-title":"Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy","volume":"55","author":"Lange","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2025.01.012_bib10","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.01.053","article-title":"Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C","volume":"140","author":"Lambrecht","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2025.01.012_bib11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/gut.46.5.711","article-title":"Liver iron excess in patients with hepatocellular carcinoma developed on viral C cirrhosis","volume":"46","author":"Chapoutot","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.jfma.2025.01.012_bib12","first-page":"1367","article-title":"Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C","volume":"91","author":"Ikura","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jfma.2025.01.012_bib13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3138\/canlivj-2022-0042","article-title":"Effect of viral eradication with direct-acting antiviral agents on iron parameters in patients with chronic hepatitis c and hyperferritinemia","volume":"6","author":"Castiella","year":"2023","journal-title":"Can Liver J"},{"key":"10.1016\/j.jfma.2025.01.012_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76871-z","article-title":"Evolution of ferritin levels in hepatitis C patients treated with antivirals","volume":"10","author":"Chang","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2025.01.012_bib15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2025.01.012_bib16","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.01.012_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29675","article-title":"Four weeks of off-treatment follow-up is sufficient to determine virologic responses at off-treatment week 12 in patients with hepatitis C virus infection receiving fixed-dose pangenotypic direct-acting antivirals","volume":"96","author":"Liu","year":"2024","journal-title":"J Med Virol"},{"key":"10.1016\/j.jfma.2025.01.012_bib18","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1128\/JCM.03548-14","article-title":"Comparison of Abbott RealTime HCV Genotype II with Versant line probe assay 2.0 for hepatitis C virus genotyping","volume":"53","author":"Liu","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jfma.2025.01.012_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum alanine aminotransferase levels","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2025.01.012_bib20","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.01.012_bib21","article-title":"Factors associated with pre-treatment hyperferritinemia in patients with chronic hepatitis C virus infection","volume":"14","author":"Chang","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2025.01.012_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2008.02.008","article-title":"Non-invasive evaluation of liver fibrosis using transient elastography","volume":"48","author":"Castera","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.01.012_bib23","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2025.01.012_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/bimj.201600107","article-title":"Optimal design of longitudinal data analysis using generalized estimating equation models","volume":"59","author":"Liu","year":"2017","journal-title":"Biom J"},{"key":"10.1016\/j.jfma.2025.01.012_bib25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/hep.20073","article-title":"Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data","volume":"39","author":"Camm\u00e0","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2025.01.012_bib26","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1038\/s41598-018-26293-9","article-title":"Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter","volume":"8","author":"Shimizu","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2025.01.012_bib27","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/apt.14554","article-title":"Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy","volume":"47","author":"Tada","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jfma.2025.01.012_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209615","article-title":"Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis","volume":"13","author":"Kawagishi","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jfma.2025.01.012_bib29","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/hepr.13899","article-title":"Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight","volume":"53","author":"Tokuchi","year":"2023","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2025.01.012_bib30","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00535-024-02101-2","article-title":"Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals","volume":"59","author":"Liu","year":"2024","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2025.01.012_bib31","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2020.11.040","article-title":"Residual risk of liver disease after hepatitis C virus eradication","volume":"74","author":"Negro","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.01.012_bib32","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMra2119758","article-title":"Hemochromatosis","volume":"387","author":"Olynyk","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.01.012_bib33","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJMoa041534","article-title":"Hemochromatosis and iron-overload screening in a racially diverse population","volume":"352","author":"Adams","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625000129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625000129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:36:32Z","timestamp":1777592192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625000129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0929664625000129"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.01.012","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term serum ferritin dynamics in patients receiving antiviral treatment for hepatitis C virus infection","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved.","name":"copyright","label":"Copyright"}]}}